3/27/2026

​

Brad Loncar

Impartiality is of the highest importance to BiotechTV. For this project, Mr. Loncar is embarking on a role in journalism. He has committed to not trading or holding individual biotechnology stocks while he is participating as a contributor to BiotechTV or while he has editorial control over it. His firm, Loncar Investments, had been index provider to two passive biotechnology-focused exchange traded funds. It has wound down this role and is no longer in this business. Loncar Investments will have no other involvement in biotech financial markets while he is a contributor to BiotechTV or while he has editorial control over it. Mr. Loncar may have consulting relationships with industry. To avoid potential conflicts, BiotechTV will not feature consulting clients during the time that Mr. Loncar is being paid a consulting fee. Current clients, who will be excluded from BiotechTV coverage during the current period, are listed below:

 

None

 

Additional future consulting work, if any, will be updated here and will follow these same guidelines so please check back to see any additional updates.

​

Regional Contributors

Regional contributors are independent contractors. It is forbidden for them to report on any company that they directly own individual stock in.

​

Ryan Flinn

Ryan Flinn is an independent contractor who contributes "Ai in Biotech" content to BiotechTV. In addition to this work, he also does communications consulting for companies in the life sciences industry. To avoid potential conflicts, he will not report on consulting clients during the time he is being paid a consulting fee. Current and recent clients, who will be excluded from his coverage, are listed below:

​

Advarra, Aitia Bio, Auron Therapeutics, Autobahn Therapeutics, BioRender, Foundery Biosciences, Freenome, Lokavant, McKesson, Radella Pharma.

​

Wassim Laroussi

Wassim Laroussi is an independent contractor who is a “Markets Correspondent” for BiotechTV. He independently creates content for BiotechTV highlighting and explaining current news, stock moves, and upcoming calendar items and catalysts of public companies, or other news related to the stock market. He may have long-term stock positions in a small handful (a maximum of 5 at any given time) of biotechnology stocks (he has a minimum holding period of one-month), which are disclosed below. His content on BiotechTV is intended to educate viewers on what is happening in the markets and/or what is ahead on the calendar, and it is not intended to be investment advice. He is not a financial advisor. While he may mention factual news related to a company he holds (for example: xyz company has earnings scheduled on Tuesday, xyz company was a top mover in biotech today) when it is in the context of such company being one of multiple companies with similar news, he will not provide in-depth commentary or analysis of a company he holds. Furthermore, when he provides in-depth commentary or analysis on a publicly traded company for BiotechTV that he does not hold, there will be a one-month cooling off period during which he has agreed to not take a position in that company. He will not have access to non-public news and does not conduct company interviews.

​

Current holdings are: RARE, KURA, AXSM, IDYA, ARQT

​

Advertisers and Sponsored Content

BiotechTV is in the business of producing independent news and educational content about the biotech industry and science. General advertisers will clearly be labeled as “Advertiser(s)” or “Sponsor(s).” If BiotechTV posts sponsored content, such content will be prominently labeled “Sponsored” or "Ad" directly on the video content itself and/or on its accompanying webpage or social media post.